# Nicotinamide Riboside's Role in Addressing Aortic Valve Disease Burden

Canonical source: https://retacompare.com/research/nicotinamide-riboside-s-role-in-addressing-aortic-valve-disease-burden

NMN & NR Supplementation · 2025-12-02


    Nicotinamide Riboside (NR) may play a role in addressing the increasing burden of non-rheumatic calcific aortic valve disease (NR-CAVD). This condition is becoming more prevalent, particularly among middle-aged and elderly populations, due to demographic changes and health inequities. Understanding the implications of NR-CAVD is crucial for longevity research, as it highlights the intersection between aging, cardiovascular health, and potential interventions.

 What this study examined

This study comprehensively assessed the global burden of NR-CAVD from 1990 to 2021, with predictions extending to 2050. It utilized data from the Global Burden of Disease (GBD) 2021, focusing on mortality, prevalence, incidence, disability-adjusted life years (DALYs), years lived with disability (YLDs), and years of life lost (YLLs). The researchers applied various statistical models, including the Joinpoint model and linear regression, to analyze trends and health inequities associated with NR-CAVD across different regions and economic contexts.

 Why this matters for longevity research

The findings of this study are significant for longevity research as they reveal the increasing burden of NR-CAVD, particularly in aging populations. With the rise of chronic diseases associated with aging, understanding the epidemiology of NR-CAVD can inform strategies to extend healthspan. As researchers explore interventions like Nicotinamide Riboside, which is known to influence NAD+ levels and sirtuin activity, insights from this study could guide future research on how to mitigate the impacts of age-related diseases.

 Key findings

The incidence and prevalence of NR-CAVD increased from 1990 to 2021 in both sexes.

Age-standardized rates of NR-CAVD are projected to decline through 2050.

Population growth was identified as the primary driver of the increasing NR-CAVD burden.

Aging was the second most significant factor contributing to the burden.

Health inequities were observed, with significant differences in NR-CAVD prevalence across regions with varying economic development levels.

The burden of NR-CAVD in middle-aged and elderly populations is expected to continue rising by 2050.

This study highlights the need for public health strategies to address the emerging challenges posed by NR-CAVD.

 The science behind it

Nicotinamide Riboside is a precursor to NAD+, a crucial coenzyme involved in various metabolic processes, including energy production and DNA repair. NAD+ plays a vital role in activating sirtuins, a family of proteins linked to longevity and cellular health. Sirtuins are known to regulate stress responses, inflammation, and metabolic health, all of which are critical in the context of cardiovascular diseases like NR-CAVD. By potentially enhancing NAD+ levels, Nicotinamide Riboside may support cardiovascular health and help mitigate age-related diseases.

 How it fits into the longevity field

This study situates NR-CAVD within the broader context of aging research, emphasizing the need for interventions that can address chronic conditions prevalent in aging populations. As researchers explore various interventions, including Nicotinamide Riboside, it is essential to consider their potential effects on cardiovascular health and overall longevity. Other related interventions, such as lifestyle modifications and pharmacological approaches targeting NAD+ metabolism, may also contribute to extending healthspan.

 Practical takeaways

Researchers and informed readers should recognize the importance of understanding the epidemiology of NR-CAVD as it relates to aging populations. The findings underscore the necessity for continued research into interventions like Nicotinamide Riboside that could potentially influence health outcomes. Additionally, addressing health inequities is crucial for developing effective public health strategies aimed at reducing the burden of NR-CAVD and other age-related diseases.

 FAQ

 What is non-rheumatic calcific aortic valve disease?

Non-rheumatic calcific aortic valve disease (NR-CAVD) is a condition characterized by the calcification and narrowing of the aortic valve, leading to impaired blood flow from the heart.

 How does population aging affect NR-CAVD?

Population aging contributes to the increasing burden of NR-CAVD, as older adults are more susceptible to cardiovascular diseases due to age-related physiological changes.

 What role does Nicotinamide Riboside play in cardiovascular health?

Nicotinamide Riboside may enhance NAD+ levels, which are important for cellular functions, including those related to cardiovascular health and longevity.

 Source: PubMed · Eur J Med Res · published 2025-12-02.

## Sources

- PubMed · Eur J Med Res: https://pubmed.ncbi.nlm.nih.gov/41331819/